

FIG. 1-1




FIG. 1-2






FIG. 1-3



The number of days after aAVC(3T3)-
NY-ESO-1 administration

FIG. 2-1




FIG. 2-2




FIG. 2-3




FIG. 2-4




FIG. 3

Promoter	No.	NY-ESO1 expression level [ng/10 ⁶ cells]	Promoter	No.	NY-ESO1 expression level [ng/10 ⁶ cells]
CMV	#01	68	Tet-on	#01	331
	#02	74		#02	106
	#03	25		#03	772
	#04	12		#04	308
	#05	11		#05	2503
	#06	10		#06	2573
	#07	26		#07	111
	#08	15		#08	7813
	#09	45		#09	7324
	#10	23		#10	7281
	#11	18		#11	17021
	#12	42		#12	710
	#13	10		#13	1094
	#14	15		#14	32
	#15	47		#15	19413
	#16	88		#16	43890
	#17	49		#17	1519
				#18	17720
				#19	114
				#20	42
				#21	3460
				#22	629
				#23	16
				#24	5
				#25	844
				#26	1566
				#27	29514
				#28	12313
				#29	995
				#30	33557
				#31	34079
				#32	29538
				#33	30602
				#34	6495
				#35	232
				#36	295
				#37	340
				#38	291
				#39	2550
				#40	747
				#41	2397
				#42	1814
				#43	683

FIG. 4-1




FIG. 4-2




FIG. 5

